The global pandemic is impacting supply chains worldwide, but pharmaceutical supply chains are especially vulnerable. Manufacturers are under pressure to help maintain the supply of critical medicines during COVID-19 as well as contribute to the on-going efforts to support the ever-changing supply chain.
As pharmaceutical manufacturers reprioritize production due to changing and increased product demand, many don’t have alternate suppliers for critical components. This has been a game-changer as they not only have to identify new suppliers, but they must also qualify these components to ensure they understand impact on process, and that quality meets the required standards.
Manufacturing partners across geographic regions are navigating this “new normal” under stressful conditions exacerbated by increased demand for APIs, new supply chain challenges, and an ever-increasing global focus on maintaining quality. To truly succeed as an industry, we must knowledge share and problem-solve together to advance and proactively prepare for the continued success of our mission as an industry.
As Co-Chairs of the 2020 ISPE Asia Pacific Pharma Manufacturing Virtual Conference & Executive Forum, we invite you to join us for this collaborative forum where you can learn and ask questions on key trends, best practices, and regulatory perspectives for maintaining pharma supply chain reliance, overall quality, and compliance sustainability.
Nowhere else can you participate in actionable, interactive discussions featuring case studies and dedicated Q&A time with experts representing FDA, MHRA, local health authorities, Pfizer, Biocon, and more as they answer questions like:
You can submit your questions on the event homepage prior to the conference or ask your questions in real-time. Stay knowledgeable throughout the year with on demand access to all session recordings and presentations for one year.
Collaboration is a crucial element in mitigating the impact of COVID-19 on the pharmaceutical supply chain. We encourage you to register today to ensure you have the strategies to make your operations more agile, compliant, and resilient to disruption.
As with all aspects of our life sciences industry, understanding how we can best meet the needs of patients with the timely delivery of life saving and sustaining products is of paramount concern. During the years since the global pandemic, the expectations and pressures on the pharmaceutical industry with respect to development, speed to market, quality and sustainability have increased...
At the 2024 ISPE Europe Annual Conference, held in Lisbon, Portugal, 16-18 April, Richard L. Friedman, MS, Deputy Director of the US Food and Drug Administration’s (US FDA) Office of Manufacturing Quality, in...
Insight from Austria’s Regulatory Authority Representative
At the 2024 ISPE Aseptic Conference, held March 12-13 in Vienna, Austria, Christina Meissner, a European Union Good Manufacturing Practice (GMP) inspector at the Austrian Agency for Health and Food Safety since 2013, and Chair of the PIC/S Drafting Group on Annex 2A and 2B, published in May 2021, offered a presentation titled...